 |
|
Two new vitamin D studies have revealed
new prescriptions for possibly preventing up to half of the cases of
breast cancer and two-thirds of the cases of colorectal cancer in the
United States. (File Photo) Photo
Gallery>>> |
WASHINGTON, Feb. 6
(Xinhua) -- Two new vitamin D studies have revealed new prescriptions for
possibly preventing up to half of the cases of breast cancer and two-thirds of
the cases of colorectal cancer in the United States.
The work was conducted by a core team of cancer
prevention specialists at the Moores Cancer Center at University of California,
San Diego, and colleagues from both coasts.
The breast cancer study, published online in the
current issue of the Journal of Steroid Biochemistry and Molecular Biology,
found that individuals with the highest blood levels of 25-hydroxyvitamin D, or
25(OH)D, had the lowest risk of breast cancer.
The researchers divided the 1,760 records of
individuals into five equal groups, from the lowest blood levels of 25(OH)D
(less than 13 nanograms per milliliter, or 13 ng/ml) to the highest
(approximately 52 ng/ml). The data also included whether or not the individual
had developed cancer.
"The data were very clear, showing that individuals
in the group with the lowest blood levels had the highest rates of breast
cancer, and the breast cancer rates dropped as the blood levels
of25-hydroxyvitamin D increased," said study co-author Cedric Garland, Dr. P.H.
"The serum level associated with a 50 percent reduction in risk could be
maintained by taking 2,000 international units of vitamin D3 daily plus, when
the weather permits, spending 10 to 15 minutes a day in the sun."
The colorectal cancer study, published online
February 6 in the American Journal of Preventive Medicine, is a meta-analysis of
five studies that explored the association of blood levels of 25(OH)D with risk
of colon cancer. All of the studies involved blood collected and tested for 25
(OH)D levels from healthy volunteer donors who were then followed for up to 25
years for development of colorectal cancer.
As with the breast cancer study, the dose-response
data on a total of 1,448 individuals were put into order by serum 25(OH)D level
and then divided into five equal groups, from the lowest blood levels to the
highest.
"Through this meta-analysis we found that raising the
serum level of 25-hydroxyvitamin D to 34 ng/ml would reduce the incidence rates
of colorectal cancer by half," said co-author Edward D. Gorham, Ph.D.
"We project a two-thirds reduction in incidence with
serum levels of 46ng/ml, which corresponds to a daily intake of 2,000 IU of
vitamin D3. This would be best achieved with a combination of diet, supplements
and 10 to 15 minutes per day in the sun," he added.
Vitamin D3 is available through diet, supplements and
exposure of the skin to sunlight, or ultraviolet B (UVB). In the paper, the
researchers also underscored the importance of limiting sun exposure such that
the skin does not change color (tan) or burn.